Latest Healthcare News

EPX Limited has landed a significant seven-year contract worth over A$5 million to deploy its EDGE technology across 10 healthcare facilities in the UAE, aiming to boost energy efficiency and sustainability.

InFocus Group Holdings has locked in up to AUD 1.7 million in potential revenues through new contracts in healthcare and logistics, underpinning its operational expansion in Southeast Asia.

Ramsay Health Care has clarified that its underlying earnings for FY25 aligned closely with market consensus, despite a significant non-cash impairment impacting statutory profits. The company confirms compliance with ASX disclosure rules amid share price volatility.

dorsaVi has inked a five-year sales agreement with Select Medical, opening access to over 1,900 US outpatient physical therapy centers for its FDA-approved motion analysis products. This follows a successful 18-month pilot validating clinical benefits in athlete rehabilitation.

The US Centers for Medicare & Medicaid Services has recommended a final reimbursement price of US$1,328 for Pacific Edge’s advanced bladder cancer diagnostic test, Cxbladder Triage Plus, marking a significant increase from earlier proposals.

Nanoveu Limited reveals significant progress in its ECS-DoT system-on-chip technology, showcasing a 60% average increase in drone flight endurance and advancing production with TSMC’s 16nm process. The company’s latest investor webinar highlights its growing OEM partnerships and disruptive edge AI capabilities.

Artrya Limited has raised A$75 million through a two-tranche placement and launched a A$5 million share purchase plan to fast-track the U.S. commercialisation of its AI-powered Salix platform following FDA clearance.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

Orthocell Limited reports an 81.1% overall treatment success rate from its Remplir Real World Evidence study, reinforcing the product’s safety and efficacy as it expands sales in the US and prepares regulatory submissions for the EU and UK.

4DMedical has secured multi-year agreements to deploy its advanced lung imaging technology across Brazil and Australia, supporting national lung cancer screening programs and enhancing lung health diagnostics.

Proteomics International has unveiled new clinical data confirming its PromarkerEso blood test can accurately detect early stages of esophageal adenocarcinoma, potentially transforming screening for a cancer with poor prognosis.

Memphasys has inked a five-year exclusive distribution agreement with Middle East leader ITL, unlocking a $325,000 initial order for its Felix™ fertility system upon CE Mark approval. This deal opens access to 15 countries and over 350 IVF clinics, setting the stage for rapid regional adoption.